Evaluation of CAE on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002792

Enrollment

100

Registered

2018-04-12

Start date

2017-04-18

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Subjects will be randomized to receive Citrus aurantium extract tablet 200mg or placebo. Subjects will orally self-adminster Citrus aurantium extract tablet 200mg or placebo twice

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subject who have decreased CERAD-K(Consortium to Establish a Registry for Alzheimer’s Disease-Korean version) memory score(-1.0SD<=CERAD-K memory score) comparing to the same age and education group.

Exclusion criteria

Exclusion criteria: 1. People who are being hospitalized or within 3 months after hospital discharge for any types of malignant tumors, severe cardiovascular diseases (stroke, hemorrhage, etc), and sever heart diseases (unstable angina, myocardial infarction, heart failure, arrhythmias requiring treatments). 2. People who have major depressive disorders categorized by Diagnostic and Statistical Manual of Mental Disorders-IV 3.People who have poor cognitive function and have Alzheimer’s disease, Parkinson’s disease, or stroke. (The diagnosis of Alzheimer’s disease is based on Diagnostic and Statistical Manual of Mental Disorders-IV)

Design outcomes

Primary

Measure	Time frame
ADAS-cog(Alzheimer’s Disease Assessment Scale-Korean version-cognitive subscale) memory	—

Secondary

Measure	Time frame
Adverse Event	—

Countries

Korea, Republic of

Contacts

Public ContactJong Paik

Kyung Hee University Hospital

paikjw@gmail.com+82-2-958-8419

Outcome results